Trends in Intravenous Antibiotic Duration for Urinary Tract Infections in Young Infants

Pediatrics
William W Lewis-de Los AngelesSameer J Patel

Abstract

To assess trends in the duration of intravenous (IV) antibiotics for urinary tract infections (UTIs) in infants ≤60 days old between 2005 and 2015 and determine if the duration of IV antibiotic treatment is associated with readmission. Retrospective analysis of infants ≤60 days old diagnosed with a UTI who were admitted to a children's hospital and received IV antibiotics. Infants were excluded if they had a previous surgery or comorbidities, bacteremia, or admission to the ICU. Data were analyzed from the Pediatric Health Information System database from 2005 through 2015. The primary outcome was readmission within 30 days for a UTI. The proportion of infants ≤60 days old receiving 4 or more days of IV antibiotics (long IV treatment) decreased from 50% in 2005 to 19% in 2015. The proportion of infants ≤60 days old receiving long IV treatment at 46 children's hospitals varied between 3% and 59% and did not correlate with readmission (correlation coefficient 0.13; P = .37). In multivariable analysis, readmission for a UTI was associated with younger age and female sex but not duration of IV antibiotic therapy (adjusted odds ratio for long IV treatment: 0.93 [95% confidence interval 0.52-1.67]). The proportion of infants ≤60 days...Continue Reading

References

Jul 6, 2007·BMJ : British Medical Journal·Giovanni MontiniGraziella Zacchello
Aug 17, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·John David SpencerDavid S Hains
Oct 10, 2013·The Pediatric Infectious Disease Journal·William Bonadio, Gary Maida
Dec 12, 2013·The Pediatric Infectious Disease Journal·Tara L GreenhowRobert H Pantell
Jul 22, 2014·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Alan R Schroeder, Shawn L Ralston
Aug 28, 2014·Pediatric Emergency Care·David SchnadowerUNKNOWN American Academy of Pediatrics Pediatric Emergency Medicine Collaborative Research Committee UTI Study Group

❮ Previous
Next ❯

Citations

Jul 5, 2018·Journal of Paediatrics and Child Health·David Isaacs
Mar 3, 2020·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Pearl W ChangAlan R Schroeder
May 28, 2019·Pilot and Feasibility Studies·Irit R RasoolyUNKNOWN Pediatric Research in Inpatient Settings (PRIS) Network
Jun 14, 2020·Hospital Pediatrics·Tiffany L StrombergHayden T Schwenk
Aug 21, 2020·Hospital Pediatrics·Neha S Joshi, Marie E Wang
Aug 21, 2020·Hospital Pediatrics·Sheila SwartzPeter Havens
Aug 21, 2020·Hospital Pediatrics·Melanie C MarshCara Haberman
Jul 6, 2020·European Journal of Pediatrics·Michael BuettcherThomas J Neuhaus
Dec 29, 2020·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Courtney Benjamin WolkUNKNOWN Pediatric Research in Inpatient Settings (PRIS) Network
Feb 18, 2021·Journal of the Pediatric Infectious Diseases Society·Marie E WangAlan R Schroeder
May 6, 2021·Hospital Pediatrics·Charlotte M BrownJames C Gay
Aug 28, 2021·Hospital Pediatrics·Nassr NamaUNKNOWN INSIGHTSCOPE TEAM
Aug 23, 2019·Pediatrics·Sanyukta DesaiUNKNOWN FEBRILE YOUNG INFANT RESEARCH COLLABORATIVE
Aug 23, 2019·Pediatrics·Natalia V Leva, Hillary L Copp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.